Lilly was founded in 1876, with Headquarters located in Indianapolis, Indiana, U.S.A and with operations based in the US and EU, Eli Lilly is now the 10th largest pharmaceutical company in the world. Across the globe, Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines at lower costs. Eli Lilly is a research-based pharmaceutical company committed to create value for all  stakeholders by accelerating the flow of innovative medicines that provide improved outcomes for individual patients and to help people live longer, healthier, more active lives.

Eli Lilly employs approximately 38,000 people worldwide. Approximately 7,400 employees are engaged in research and development. Clinical research is being conducted in more than 55 countries, with research and development facilities located in 8 countries and manufacturing plants located in 13 countries. Lilly products are marketed in 125 countries.

Lilly focuses on diabetology, oncology, and internal medicine. Witihin internal medicine, Lilly has a deep interest in the field of muscle waste, with a number of potential drugs in preclinical and clinical development. With this focus on muscle, Lilly is necessarily interested in physical frailty and sarcopenia as one of the potential major indications of the future.